Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BIIB logo BIIB
Upturn stock ratingUpturn stock rating
BIIB logo

Biogen Inc (BIIB)

Upturn stock ratingUpturn stock rating
$127.04
Last Close (24-hour delay)
Profit since last BUY-4.3%
upturn advisory
WEAK BUY
BUY since 16 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/20/2025: BIIB (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -9.89%
Avg. Invested days 35
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/20/2025

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 18.61B USD
Price to earnings Ratio 12.54
1Y Target Price 171.95
Price to earnings Ratio 12.54
1Y Target Price 171.95
Volume (30-day avg) 1632113
Beta 0.15
52 Weeks Range 110.04 - 238.00
Updated Date 06/22/2025
52 Weeks Range 110.04 - 238.00
Updated Date 06/22/2025
Dividends yield (FY) -
Basic EPS (TTM) 10.13

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 15.07%
Operating Margin (TTM) 28.05%

Management Effectiveness

Return on Assets (TTM) 5.43%
Return on Equity (TTM) 9.19%

Valuation

Trailing PE 12.54
Forward PE 8.5
Enterprise Value 22637795777
Price to Sales(TTM) 1.9
Enterprise Value 22637795777
Price to Sales(TTM) 1.9
Enterprise Value to Revenue 2.31
Enterprise Value to EBITDA 8.38
Shares Outstanding 146528000
Shares Floating 146133672
Shares Outstanding 146528000
Shares Floating 146133672
Percent Insiders 0.22
Percent Institutions 92.93

Analyst Ratings

Rating 3.81
Target Price 171.85
Buy 4
Strong Buy 13
Buy 4
Strong Buy 13
Hold 20
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Biogen Inc

stock logo

Company Overview

overview logo History and Background

Biogen Inc. was founded in 1978 in Geneva, Switzerland, by several prominent biologists, including Nobel laureates Walter Gilbert and Phillip Sharp. Originally named Biogen N.V., the company went public in 1983 and quickly became a pioneer in biotechnology, focusing on therapies for neurological and autoimmune diseases. It has evolved through strategic partnerships, acquisitions, and a focus on innovative drug development.

business area logo Core Business Areas

  • Neurology: Focuses on treatments for neurological diseases, including multiple sclerosis (MS), spinal muscular atrophy (SMA), and Alzheimer's disease.
  • Biosimilars: Develops and commercializes biosimilar versions of existing biologic drugs to provide more affordable treatment options.
  • Rare Diseases: Developing new treatments to address unmet needs in rare diseases.

leadership logo Leadership and Structure

The leadership team includes the CEO, Priya Singhal, MD. The company has a board of directors overseeing its strategic direction. The organizational structure is divided into research and development, commercial operations, and corporate functions.

Top Products and Market Share

overview logo Key Offerings

  • Spinraza: A treatment for spinal muscular atrophy (SMA). Competitors include Novartis' Zolgensma and Roche's Evrysdi. Revenue for 2023 was $1.68 billion. Global market share of SMA treatment is around 40%.
  • Tysabri: A treatment for multiple sclerosis (MS). Competitors include Roche's Ocrevus and Novartis' Gilenya. Tysabri revenue for 2023 was $1.69 billion. This represents about 10% market share.
  • Aduhelm: An antibody for the treatment of Alzheimer's disease. The drug's efficacy has been controversial, leading to limited market adoption. Competitors include Eisai's and Biogen's Leqembi (lecanemab).
  • Tecfidera: A treatment for multiple sclerosis (MS), an oral fumarate therapy. Several generic products entered the market after patent expiry. Sales have drastically declined in recent years. Competitors include Novartis' Gilenya, Roche's Ocrevus, and generic versions of Tecfidera.
  • Leqembi: A treatment for early Alzheimer's disease, developed in partnership with Eisai. Market adoption is gradually increasing. Competitors include Eli Lilly's donanemab.

Market Dynamics

industry overview logo Industry Overview

The biotechnology industry is characterized by intense competition, rapid technological advancements, and high regulatory hurdles. Key trends include personalized medicine, gene therapy, and the development of biosimilars.

Positioning

Biogen is a leading biotechnology company with a strong focus on neurological disorders. It has a reputation for innovation and a robust pipeline of potential new therapies.

Total Addressable Market (TAM)

The total addressable market for neurological disease treatments is projected to reach hundreds of billions of dollars. Biogen is well-positioned to capture a significant share of this market through its existing portfolio and pipeline.

Upturn SWOT Analysis

Strengths

  • Strong research and development capabilities
  • Established presence in the neurology market
  • Partnerships with leading research institutions
  • Diverse product portfolio
  • Expertise in biologics development

Weaknesses

  • Reliance on a few key products
  • Exposure to generic competition
  • Controversies surrounding some products
  • High research and development costs
  • Patent expirations

Opportunities

  • Expanding into new therapeutic areas
  • Developing innovative gene therapies
  • Leveraging biosimilar expertise
  • Strategic acquisitions to expand pipeline
  • Partnerships with emerging biotechnology companies

Threats

  • Increasing competition from other biotechnology companies
  • Regulatory challenges
  • Pricing pressures
  • Clinical trial failures
  • Changes in healthcare policies

Competitors and Market Share

competitor logo Key Competitors

  • Roche (ROG.SW)
  • Novartis (NOVN.SW)
  • Eli Lilly (LLY)

Competitive Landscape

Biogen faces intense competition, especially in the MS market. Leqembi offers a potential advantage in Alzheimer's disease. Roche and Novartis are diversified pharmaceutical companies with broader portfolios.

Major Acquisitions

Reata Pharmaceuticals

  • Year: 2023
  • Acquisition Price (USD millions): 7300
  • Strategic Rationale: Acquisition of Reata brings Skyclarys, a first-in-class therapy for Friedreich's ataxia (FA), a rare neurodegenerative disorder, expanding Biogen's rare disease portfolio.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been impacted by generic competition and the performance of new product launches.

Future Projections: Analysts project moderate revenue growth driven by Leqembi and other pipeline products.

Recent Initiatives: Focus on Alzheimer's disease with Leqembi and pipeline expansion in neurological disorders.

Summary

Biogen is a leading biotechnology company with a strong legacy in neurology. While facing challenges from generic competition and controversies surrounding some of its products, the company is strategically focused on expanding its pipeline and diversifying its portfolio, particularly in Alzheimer's disease with Leqembi. The acquisition of Reata Pharmaceuticals expands Biogen's rare disease portfolio. The company needs to successfully commercialize Leqembi and manage its patent expirations to achieve sustained growth.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings (SEC)
  • Analyst Reports
  • Industry Publications

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Market conditions and company performance are subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Biogen Inc

Exchange NASDAQ
Headquaters Cambridge, MA, United States
IPO Launch date 1991-09-16
President, CEO & Director Mr. Christopher A. Viehbacher
Sector Healthcare
Industry Drug Manufacturers - General
Full time employees 7605
Full time employees 7605

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.